Browsing by Subject "Disease modeling"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Open Access
    Patient iPSC-derived retinal organoids: Observable retinal diseases in-a-dish
    (Universidad de Murcia, Departamento de Biologia Celular e Histiologia, 2021) Zhang, Xiao-Hui; Jin, Zi-Bing
    Induced pluripotent stem cells (iPSCs), reprogrammed from human somatic cells, hold the capacity to differentiate into most human body cells. iPSCs can be differentiated into retinal organoids, a three-dimensional structured retina containing various retinal cells. Patient-specific retinal organoids provide a powerful disease model to recapitulate the disease to study the pathogenesis of inherited retinal dystrophies, to screen or discover new drugs, and most importantly to supply an unlimited cell source for retinal regeneration
  • Thumbnail Image
    Publication
    Open Access
    Prospects of induced pluripotent stem cells in treating advancing Alzheimer’s disease: A review
    (Universidad de Murcia, Departamento de Biologia Celular e Histiologia, 2025) Park, Juyoun Janis; Rim, Yeri Alice; Sohn, Yeowon; Nam, Yoojun; Ju, Ji Hyeon
    The World Health Organization has identified Alzheimer’s disease (AD), the leading cause of dementia globally, as a public health priority. However, the complex multifactorial pathology of AD means that its etiology remains incompletely understood. Despite being recognized a century ago, incomplete knowledge has hindered the development of effective treatments for AD. Recent scientific advancements, particularly in induced pluripotent stem cell (iPSC) technology, show great promise in elucidating the fundamental mechanisms of AD. iPSCs play a dual role in regenerating damaged cells for therapeutic purposes and creating disease models to understand AD pathology and aid in drug screening. Nevertheless, as an emerging field, iPSC technology requires further technological advancement to develop effective AD treatments in the future. Thus, this review summarizes recent advances in stem cell therapies, specifically iPSCs, aimed at understanding AD pathology and developing treatments